Who are Reversal of superficial neuromuscular blockade's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/reversal-of-superficial-neuromuscular-blockade.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Reversal of superficial neuromuscular blockade — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Reversal of superficial neuromuscular blockade (Reversal of superficial neuromuscular blockade) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Neuromuscular blockade reversal agent. Area: Anesthesiology.

marketed Neuromuscular blockade reversal agent Acetylcholinesterase or neuromuscular blocking agents (depending on specific agent) Anesthesiology Small molecule Live · refreshed every 30 min

Target snapshot

Reversal of superficial neuromuscular blockade (Reversal of superficial neuromuscular blockade) — Pontificia Universidade Catolica de Sao Paulo. This drug reverses neuromuscular blockade by antagonizing the effects of neuromuscular blocking agents at the neuromuscular junction.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Reversal of superficial neuromuscular blockade TARGET	Reversal of superficial neuromuscular blockade	Pontificia Universidade Catolica de Sao Paulo	marketed	Neuromuscular blockade reversal agent	Acetylcholinesterase or neuromuscular blocking agents (depending on specific agent)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Neuromuscular blockade reversal agent class)

Pontificia Universidade Catolica de Sao Paulo · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Reversal of superficial neuromuscular blockade — Competitive Intelligence Brief. https://druglandscape.com/ci/reversal-of-superficial-neuromuscular-blockade. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab